logo-loader

VolitionRx CEO to present coronavirus white blood cell research at Maxim Group virtual conference

Published: 11:21 27 May 2020 EDT

Coronavirus graphic
VolitionRx is currently clinically testing whether elevated levels of neuroendocrine tumors in the blood are predictive of complications arising from viral infections such as COVID-19

VolitionRx Limited (NYSEAMERICAN:VNRX) announced Wednesday that CEO Cameron Reynolds has been invited to give a presentation on coronavirus testing Wednesday at The Role of Cell Therapy and Clarity on Testing Conference.

The virtual event, put on by the Maxim Group, runs from 10 am to 2 pm ET. Reynolds is part of a panel discussion titled “Testing & Susceptibility - Clearing the Air,” set to begin at noon.

Reynolds plans to talk about Volition’s research on white blood cells and their predictive potential regarding the coronavirus.

READ: VolitionRx closes $13.8M public offering to fund product development and clinical studies

Under normal circumstances, neutrophil extracellular traps (NETs) are formed by white blood cells to catch and trap invading viruses by ejecting chromatin materials. Viruses like SARS and pneumonia, though, are associated with a hyperimmune response that sees white blood cells eject massive amounts of NETs, which is damaging to the lungs.

VolitionRx is currently clinically testing whether elevated levels of neuroendocrine tumors (NETs) in the blood are predictive of complications arising from viral infections such as COVID-19. 

So far, a proof of concept study of 34 coronavirus patients and 50 control group subjects revealed that nucleosomes, a basic structural unit of DNA, were highly elevated in those with the virus.

A preliminary study showed an area under the curve (AUC) — a measure of drug exposure — for one of its NU.Q assays of 98.7% for PCR positive COVID versus the control group with 100% sensitivity and 94% specificity. A second assay showed an AUC of 86.2%.

The company plans to use the results of this trial and other ongoing studies to further its efforts to develop a clinically useful product to help mitigate the pandemic, the company said.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

9 hours, 2 minutes ago